Hanmi Pharmaceutical Company Limited
Clinical trials sponsored by Hanmi Pharmaceutical Company Limited, explained in plain language.
-
New obesity drug HM15275 shows promise in Mid-Stage trial
Disease control OngoingThis study tests a new medicine called HM15275 to help people with obesity or overweight lose weight. About 267 adults without diabetes will receive either the drug or a placebo for 36 weeks. The main goal is to see how much weight changes from the start to the end of treatment.
Phase: PHASE2 • Sponsor: Hanmi Pharmaceutical Company Limited • Aim: Disease control
Last updated May 17, 2026 06:21 UTC
-
New weekly shot aims to tame rare low-blood-sugar disease in kids and adults
Disease control OngoingThis study tests a new drug called HM15136 in people aged 2 and older with congenital hyperinsulinism, a rare condition that causes dangerously low blood sugar. The drug is given as a weekly shot for 8 weeks, on top of their usual treatments. The goal is to see if it is safe and …
Phase: PHASE2 • Sponsor: Hanmi Pharmaceutical Company Limited • Aim: Disease control
Last updated May 17, 2026 06:17 UTC
-
Could this new drug reverse fatty liver damage? phase 2 trial underway
Disease control OngoingThis study tests a new medicine called HM15211 (Efocipegtrutide) in 215 adults with NASH, a serious fatty liver disease with scarring. Participants receive either the drug or a placebo for 12 months. The main goal is to see if the drug can clear the liver inflammation without mak…
Phase: PHASE2 • Sponsor: Hanmi Pharmaceutical Company Limited • Aim: Disease control
Last updated May 11, 2026 20:38 UTC